Navigation Links
Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy
Date:5/20/2011

SEATTLE Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment. Researchers at Fred Hutchinson Cancer Research Center reported at today's annual meeting of the American Society of Gene and Cell Therapy in Seattle that one possible approach to reduce this toxic effect on bone marrow cells is to modify the cells with a gene that makes them resistant to chemotherapy.

Hans-Peter Kiem, M.D., a member of the Hutchinson Center's Clinical Research Division, and colleagues Jennifer Adair, Ph.D., a research associate in the Clinical Research Division, and Maciej Mrugala, M.D., Ph.D., M.P.H., a neuro-oncololgist at the Seattle Cancer Care Alliance and the University of Washington, presented data from a clinical trial in which bone marrow stem cells from patients with brain tumors were removed and modified with a retrovirus vector to introduce the chemotherapy-resistant gene. The cells were then re-infused into the patients. In the trial, which was designed to evaluate safety and feasibility, patients were safely administered gene-modified blood stem cells that persisted for more than one year and did not show any apparent harmful effects.

This approach was first attempted in patients with a terminal form of brain cancer called glioblastoma. Currently, median survival for glioblastoma patients is just 12 to 15 months. The prognosis for glioblastoma patients is poor not only because no curative treatment is available but because doctors cannot effectively use the treatment that does exist. Glioblastoma cells make a large amount of a protein called MGMT that makes them resistant to chemotherapy, so doctors use a second drug, called benzylguanine, to knock down MGMT and make the tumor cells susceptible to the chemotherapy. However, this potent one-two punch is not limited to the brain tumor cells. Benzylguanine also disables MGMT in normal blood and bone marrow cells, leaving them also susceptible to the effects of chemotherapy. The effects on patients' blood and bone marrow can be pronounced and often limit the ability to effectively administer the chemotherapy.

"Our initial results are encouraging because our first patient is still alive and without evidence of disease progression almost two years after diagnosis," Kiem said.

The results of the trial suggest the administration of the modified cells represent a safe method for protecting marrow and blood cells from the harmful effects of chemotherapy in brain tumor patients. Future clinical trials will be done to determine whether this combination chemotherapy will also improve the survival of patients with glioblastoma.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Sections of retinas regenerated and visual function increased with stem cells from skin
2. Common anti-inflammatory coaxes liver cancer cells to commit suicide
3. Winding back the clock with kidney stem cells
4. Gene expression changes in nasal cells may help identify lung cancer in earliest stages
5. A new program for neural stem cells
6. Discovery of Lung Stem Cells May Herald New Treatments
7. UCLA scientists discover way to amp up power of killer T cells
8. Step in breakdown of HIV proteins essential to recognition, destruction of infected cells
9. Oncolytic viruses effectively target and kill pancreatic cancer stem cells
10. Wistar researchers: Direct proof of how T cells stay in standby mode
11. Normal stem cells made to look and act like cancer stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist ... whitening is among the most popular cosmetic procedures in dentistry today, but the cost ... can put them at risk of teeth whitening-related damage. For a limited time, Dr. ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of ... GRIP-DRY is a newly patented product that has solved some of the basic problems golfers ... early morning dew or right after a rain shower, might understand the struggle of placing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has struggled ... of Freedom Laser Therapy , was determined to find solutions to his problems – ... of Inventors Digest is ready to introduce his breakthrough inventions to the world ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... 2016 first quarter ended December 31, 2015. ... First Quarter Highlights , Revenue of $36.5 million ... 2015 , Domestic Radiation Measurement services revenues increased 2.8% ...
(Date:2/9/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... fourth quarter and full year 2015 financial results ... genome editing," said Edward Lanphier, Sangamo,s president and ... technology leads the therapeutic genome editing field and ... move our ground-breaking genome editing programs through IND ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology: